Literature DB >> 28315555

Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.

RuthAnn Gordon1, Mary Kate Kasler1, Kristen Stasi1, Yelena Shames1, Mimma Errante1, Kathryn Ciccolini1, Anna Skripnik Lucas1, Pam Raasch1, Erica Fischer-Cartlidge1.   

Abstract

BACKGROUND: Immunotherapy, specifically the use of checkpoint inhibitors, offers patients with cancer an alternative to chemotherapy, targeting different pathways to destroy cancer cells. The side effects of immunotherapies, as well as their impact on normal tissue, need to be assessed and managed based on their mechanisms of action.
OBJECTIVES: This article presents an overview of immune-related adverse events (AEs). 
.
METHODS: Common immune-related toxicities, as well as rare and refractory toxicities, are reviewed. 
.
FINDINGS: Immunotherapy treatment is an option for many patients with cancer, and nurses must understand the distinct side effect profile of these agents. Prompt identification and expert management are the cornerstones of success when dealing with immune-related AEs, and oncology nurses play a key role in improving patient care.

Entities:  

Keywords:  cancer immunotherapy, immune-related adverse events, checkpoint inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28315555     DOI: 10.1188/17.CJON.S2.45-52

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  10 in total

Review 1.  Immunotherapy in previously treated non-small cell lung cancer (NSCLC).

Authors:  Ticiana A Leal; Suresh S Ramalingam
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 2.  Update in TIGIT Immune-Checkpoint Role in Cancer.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

Review 3.  A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.

Authors:  Neeraj Chhabra; Joseph Kennedy
Journal:  J Med Toxicol       Date:  2021-04-07

Review 4.  Adverse Events of Oncologic Immunotherapy and Their Management.

Authors:  Fedricker Diane Barber
Journal:  Asia Pac J Oncol Nurs       Date:  2019 Jul-Sep

5.  Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.

Authors:  Ling Gao; Xi Yang; Cheng Yi; Hong Zhu
Journal:  Front Pharmacol       Date:  2019-10-17       Impact factor: 5.810

6.  Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy.

Authors:  Matthew D Biniakewitz; Mary Kate Kasler; Kristen L Fessele
Journal:  Asia Pac J Oncol Nurs       Date:  2020-11-21

7.  Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival.

Authors:  Lorena Villa-Crespo; Sebastian Podlipnik; Natalia Anglada; Clara Izquierdo; Priscila Giavedoni; Pablo Iglesias; Mireia Dominguez; Francisco Aya; Ana Arance; Josep Malvehy; Susana Puig; Cristina Carrera
Journal:  Cancers (Basel)       Date:  2022-02-27       Impact factor: 6.639

8.  Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience.

Authors:  Fedricker D Barber; Erick Campbell; Yuko Yamamura; Clover J Patterson; Audrey C Hartnett; Holly Kinahan; Victoria A Miller; Amanda L Brink; Anna Poullard; Gabriele E Urschel; Andre Brantley; Isabel G Cepeda; Poonam Goswami; Sheena Charles; Shincy Philip; Sara Bresser; Sandra Musekiwa-Adjei; Nageli Perez; Hung Le; Penny Phillips; Vivek Subbiah; Funda Meric-Bernstam; Ecaterina E Dumbrava
Journal:  J Adv Pract Oncol       Date:  2022-10-12

Review 9.  New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.

Authors:  Nagashree Seetharamu; Isabel R Preeshagul; Kevin M Sullivan
Journal:  Lung Cancer (Auckl)       Date:  2017-07-13

10.  Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.

Authors:  Náthali Felícia Mineiro Dos Santos Garrett; Ana Cristina Carvalho da Costa; Elaine Barros Ferreira; Giovanni Damiani; Paula Elaine Diniz Dos Reis; Christiane Inocêncio Vasques
Journal:  PLoS One       Date:  2021-08-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.